These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1773423)

  • 1. L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients.
    Finali G; Piccirilli M; Oliani C; Piccinin GL
    Clin Neuropharmacol; 1991 Dec; 14(6):523-36. PubMed ID: 1773423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer-type dementia and verbal memory performances: influence of selegiline therapy.
    Finali G; Piccirilli M; Oliani C; Piccinin GL
    Ital J Neurol Sci; 1992 Mar; 13(2):141-8. PubMed ID: 1592575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.
    Piccinin GL; Finali G; Piccirilli M
    Clin Neuropharmacol; 1990 Apr; 13(2):147-63. PubMed ID: 2109658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive effects of L-deprenyl in Alzheimer's disease.
    Tariot PN; Sunderland T; Weingartner H; Murphy DL; Welkowitz JA; Thompson K; Cohen RM
    Psychopharmacology (Berl); 1987; 91(4):489-95. PubMed ID: 3108930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial.
    Burke WJ; Roccaforte WH; Wengel SP; Bayer BL; Ranno AE; Willcockson NK
    J Am Geriatr Soc; 1993 Nov; 41(11):1219-25. PubMed ID: 8227897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results.
    Burke WJ; Ranno AE; Roccaforte WH; Wengel SP; Bayer BL; Willcockson NK
    J Am Geriatr Soc; 1993 Apr; 41(4):367-70. PubMed ID: 8463521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological correlates of L-deprenyl therapy in idiopathic parkinsonism.
    Finali G; Piccirilli M; Piccinin GL
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jan; 18(1):115-28. PubMed ID: 8115667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.
    Mangoni A; Grassi MP; Frattola L; Piolti R; Bassi S; Motta A; Marcone A; Smirne S
    Eur Neurol; 1991; 31(2):100-7. PubMed ID: 1904354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects.
    Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG
    Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
    Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.
    Sevush S; Guterman A; Villalon AV
    J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of low-dose L-deprenyl in Alzheimer's disease.
    Schneider LS; Pollock VE; Zemansky MF; Gleason RP; Palmer R; Sloane RB
    J Geriatr Psychiatry Neurol; 1991; 4(3):143-8. PubMed ID: 1953966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2000; (2):CD000442. PubMed ID: 10796544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging.
    Estévez-González A; Kulisevsky J; Boltes A; Otermín P; García-Sánchez C
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1021-8. PubMed ID: 14618554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memory dysfunction and word priming in dementia and amnesia.
    Shimamura AP; Salmon DP; Squire LR; Butters N
    Behav Neurosci; 1987 Jun; 101(3):347-51. PubMed ID: 2955793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline and cognitive function in Parkinson's disease.
    Hietanen MH
    Acta Neurol Scand; 1991 Nov; 84(5):407-10. PubMed ID: 1776388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study.
    Agnoli A; Fabbrini G; Fioravanti M; Martucci N
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):31-5. PubMed ID: 1638171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.